Vertex's Q1 2026 earnings call highlighted strong overall growth, driven by the CF franchise and new product launches (Casgevi, Journavix). The company reiterated its full-year guidance and emphasized the potential of its emerging renal franchise (POVI) as a future growth driver. Key pipeline updates included the discontinuation of the VX522 mRNA therapy and progress in expanding labels for CFTR modulators. Q1 revenue grew 8% YoY to $2.99B, meeting expectations.
Vertex's Q1 2026 earnings call highlighted strong overall growth, driven by the CF franchise and new product launches (Casgevi, Journavix). The company reiterated its full-year guidance and emphasized the potential of its emerging renal franchise (POVI) as a future growth driver. Key pipeline updates included the discontinuation of the VX522 mRNA therapy and progress in expanding labels for CFTR modulators. Q1 revenue grew 8% YoY to $2.99B, meeting expectations.
Vertex's Q1 2026 earnings call highlighted strong overall growth, driven by the CF franchise and new product launches (Casgevi, Journavix). The company reiterated its full-year guidance and emphasized the potential of its emerging renal franchise (POVI) as a future growth…
Q1 revenue grew 8% YoY to $2.99B, meeting expectations.
Non-CF products (Casgevi, Journavix) now contribute ~25% of product revenue growth.
Guidance · revenue to $13.025B
Management's guidance tone is positive, with reiterated revenue targets and strong launch momentum across non-CF products (Casgevi, Journavix), indicating a healthy growth trajectory.
Management mentioned ongoing investments in manufacturing network and process development for various products, reflected in the gross margin outlook, but provided no specific capex figures or directional change.
Management expressed strong confidence in execution, highlighted multiple successful milestones, and reiterated guidance with upbeat language like 'terrific start' and 'sparkling' results.
“We previously disclosed tolerability issues in this program. Despite actions we have taken in the trial to overcome these issues, we have not been able to do so. and as such, we have chosen to discontinue the program.”
“Importantly, we worked on securing a pricing agreement for Casgevi in Germany in Q1 and are currently working through the implementation steps. This is a historic moment”
“This is a significant expansion of eligibility that reflects decades of investment, effort, and a relentless pursuit of the science. It is also a great example of innovation... to expand the benefit of vertex CFTR modulators to about 95% o…”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Revenue | FY2026 | $12.95B–$13.1B | $13.025B | MAINTAINED |
Vertex discontinued its VX522 mRNA therapy for CF due to tolerability issues (lung inflammation from the LNP delivery), establishing that LNP-based inhaled delivery remains an unsolved problem for the last ~5,000 CF patients who produce no CFTR protein. — This indicates a persistent limitation of current LNP delivery technology, which could affect the pipeline strategies of other companies working on inhaled mRNA therapies.
… behind VX828 in the family of next-gen 3.0 are VX581 and VX272. both of which are currently in the clinic in Phase 1 Healthy Volunteer Studies. As we have consistently said, if it is possible to do better in CF, we're committed to being the ones who do so. And finally, on VX522, the mRNA therapy we've been developing for people who produce no CFTR protein and therefore cannot benefit from our modulators. We previously disclosed tolerability issues in this program. Despite actions we have taken in the trial to overcome these issues, we have not been able to do so. and as such, we have chosen to discontinue the program. Given this early termination, we will not be able to assess the efficacy or full safety of VX522. We will be working with sites to close out the study in the coming weeks. Moving on to our renal franchise, which continues to make quick progress and is rapidly establishing itself as Vertex's fourth franchise along CF, heme, and pain. In total, we have four programs in mid- and late-stage development in renal, POVI and IGAN, POVI in primary membranous nephropathy, inoxiplin in AMKD, and VX407 in ADPKD. Tonight, I'll cover the first three programs, starting with …
Vertex reached pricing agreement for Casgevi in Germany in Q1, a historic moment for the treatment, indicating successful reimbursement negotiations in a major European market. — This de-risks the European rollout for Casgevi and could pressure competitors' pricing strategies in the ex-US gene therapy market.
… to heme, the rollout of CasGevi continues to gather momentum across all three regions, and I'm pleased to highlight another significant commercial milestone since launch. Over 500 patients have now initiated the CasGevi treatment journey. Hundreds have had their first cell collection, and many patients have had their cells edited and are ready for infusion. During the first quarter, we delivered $43 million in CasGevi revenue. Importantly, we worked on securing a pricing agreement for Casgevi in Germany in Q1 and are currently working through the implementation steps. This is a historic moment and we're excited that German patients with sickle cell disease and TDT may soon be benefiting from long-term access to Casgevi at a sustainable price. Overall, we are very encouraged by the robust flow of patients in the US, in Europe, and the Middle East moving from referral to cell collection and infusion. First quarter revenue reflects expected variability quarter to quarter as patients choose the timing for their infusion that suits them best. For the full year 2026, the Casgevi outlook is very promising, as we have built our ATC network, secured reimbursements, and now have many …